Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
Glucose-lowering therapies linked to reduced risk for CV events in type 2 diabetes, MASLD
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.
Dry January campaign aims to make ‘first step’ toward abstinence less daunting
Each January, Alcohol Change UK runs Dry January, a post-holiday campaign that encourages people to abstain from alcohol for 31 days at the beginning of the year and drink more healthily year-round.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Investigational FGF-21 improves liver fat, glycemic control markers in MASH, diabetes
BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.
ACG publishes new guideline for management of alcohol-associated liver disease
A new clinical guideline published in the American Journal of Gastroenterology underscored the need to overcome barriers to alcohol use disorder treatment and expand multidisciplinary care for patients with alcohol-associated liver disease.
VIDEO: NAFLD upgrade to MASLD offers ‘less stigmatizing’ positive diagnosis for patients
In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted how rebranding nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease offers a “positive diagnosis” without the associated stigma.
Nomenclature change brings new opportunities for research, drug development
The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.
No patient left behind: MASLD rebranding provides ‘affirmative diagnosis’ without stigma
In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.
Researchers advise limit of 7.4 grams of alcohol per day in early steatotic liver disease
Researchers recommended that patients with steatotic liver disease who are at a lower risk for advanced cirrhosis should consume no more than 7.4 grams of alcohol per day, the equivalent of a half a 12 oz. beer or half a glass of wine.
More education needed to help PCPs ‘feel confident’ treating, managing MASLD
BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.
Women with food insecurity, low BMI more likely to have hepatic steatosis
BOSTON — Women who experience food insecurity and have a BMI less than 25 kg/m2 had higher odds of hepatic steatosis compared with overweight women or those with obesity, regardless of HIV status, according to research at The Liver Meeting.
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read